Amneal Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Amneal Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 50.3 times by its yearly operating cash. Higher than 95% of Healthcare companies in United States.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 34% of its market value (net debt). Lower than 89% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
3.8×Over the last 3 years its own operating cash covered its investment spending (capex) 3.8 times.
Higher than 82% of Healthcare companies in United States.
Cash Locked Ratio
$41For every $100 of sales, $41 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $52 tied up three years earlier.
More money tied up than 83% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$25Sales grew 36% in 3 years; of every extra $100 of sales, $25 became extra profit.
Higher than 55% of Healthcare companies in United States.
Asset Productivity Ratio
+36% / -3%In 3 years sales changed by +36% while total assets changed by -3%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
50.3×Debt due within a year is covered 50.3 times by its yearly operating cash.
Higher than 95% of Healthcare companies in United States.
Cash Cushion Ratio
−34%Debt, after subtracting cash, equals 34% of its market value (net debt).
Lower than 89% of Healthcare companies in United States.
Tangible Assets Ratio
68%Of every $100 the company owns, $68 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 64% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Amneal Pharmaceuticals, Inc. owes $0.99 for every $1 it owns. Amneal Pharmaceuticals, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
41.8Investors pay $41.8 for every $1 of Amneal Pharmaceuticals, Inc.'s yearly profit, higher than 75% of Healthcare companies in United States.
P/B ratio
216.00The share price is 216.00 times Amneal Pharmaceuticals, Inc.'s book value per share, higher than almost all Healthcare companies in United States.
Market cap
$7.1 BThe total market value of all of Amneal Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 87% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$33 MWhat Amneal Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.09Net worth divided by the number of shares. The share price of $20.48 is 216.0 times this, which is the P/B above.
Return on equity (ROE)
613.0%Amneal Pharmaceuticals, Inc. earned 613.0% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
Owes vs Owns
0.99×Amneal Pharmaceuticals, Inc. owes $0.99 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Dividend yield
NoneAmneal Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+8%Revenue rose 8% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Profit growth
Back to profitAmneal Pharmaceuticals, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
2.4%Amneal Pharmaceuticals, Inc. keeps $2 of every $100 of revenue as net profit.
Cash quality
4.7×Cash from Amneal Pharmaceuticals, Inc.'s business was 4.7× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
1.7×Amneal Pharmaceuticals, Inc.'s operating profit covered its interest costs 1.7 times in the year to Dec 2025.
Cash vs debt
Net debtAmneal Pharmaceuticals, Inc. had $2.4 B more debt than cash (net debt) at Dec 2025.
Questions
What is Amneal Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $41.8 for every $1 of Amneal Pharmaceuticals, Inc.'s yearly profit, higher than 75% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Amneal Pharmaceuticals, Inc.: $7.1 B ÷ $33 M (30 Jun 2026) = 216.0.
What is Amneal Pharmaceuticals, Inc.'s return on equity?
Amneal Pharmaceuticals, Inc. earned 613.0% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
How much does Amneal Pharmaceuticals, Inc. owe compared with what it owns?
Amneal Pharmaceuticals, Inc. owes $0.99 for every $1 it owns (high), higher than 86% of Healthcare companies in United States.
Does Amneal Pharmaceuticals, Inc. pay a dividend?
No. Amneal Pharmaceuticals, Inc. does not currently pay a dividend.
Is Amneal Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 8% in the year to Dec 2025, and grew 11% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.